SAR442970
ACT16852
Phase 2 small_molecule completed
Quick answer
SAR442970 for Hidradenitis Suppurativa is a Phase 2 program (small_molecule) at Sanofi Pasteur with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Sanofi Pasteur
- Indication
- Hidradenitis Suppurativa
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed